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Background: The aim of this study was to evaluate the association between obesity and infected bile or bacteremia in
patients with acute calculous cholecystitis.
Methods: Authors analyzed the medical records of 139 patients who had undergone cholecystectomy for the
treatment of acute calculous cholecystitis from January 2007 to June 2013 in a single teaching hospital. Association of
body mass index (BMI) with bactibilia and bacteremia was assessed using univariate and multivariate analysis. Clinical
findings and biliary infection related data were recorded for the following variables: gender, age, alcohol and smoking
history, the results of blood and bile cultures, cholesterolosis, diabetes, hypertension, and duration of the hospital stay.
Results: The microbial culture rate of bactibilia and bacteremia were 50.4% and 21.6%, respectively. In the univariate
analysis, bacteremia was associated with bactibilia (OR: 4.33, p = 0.002). In the multivariate analysis for the risk factors of
bactibilia, BMI and bacteremia were related with bactibilia (OR: 0.59, 95% CI: 0.42-0.84, p = 0.003) (OR: 3.32, 95% CI: 1.22-9,
p = 0.02). In the multivariate analysis for the risk factors of bacteremia, BMI, bactibilia and age were related with
bacteremia (OR: 0.76, 95% CI: 0.59-0.99, p = 0.04) (OR: 3.46, 95% CI: 1.27-9.45, p = 0.02) (OR: 1.05, 95% CI: 1.01-1.09, p = 0.02).
Conclusion: In this retrospective study, BMI was inversely correlated with bacteremia or bactibilia, which means obese
or overweight patients are less likely to be associated with bacteremia or bactibilia in patients with acute calculous
cholecystitis.
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Obesity is a well-established risk factor for cholesterol
gallstone and subsequent cholecystectomy [1-4]. This is
because of the increased cholesterol synthesis or secre-
tion associated with glucose intolerance and insulin re-
sistance [2,5]. Gallbladder (GB) hypomotility secondary
to obesity or autonomic neuropathy has also been pro-
posed as one of the mechanisms [6,7]. However, the as-
sociation between obesity and bactibilia or bacteremia,
which have been postulated as one of the mechanisms or
manifestations of cholecystitis remains unclear. Selecting
empirical antibiotics in patients with bactibilia or bac-
teremia is also important.* Correspondence: jaihoonyoon@gmail.com
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unless otherwise stated.The present study aims to provide an association be-
tween obesity and bactibilia or bacteremia in patients
with acute calculous cholecystitis and to obtain isolated
bacterial profiles of bile and blood to help direct empir-
ical therapy.Methods
Ethics statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki and approved
by institutional review board of Chuncheon Sacred Heart
hospital before initiating study (2013–84). Patient records
or information was anonymized and de-identified prior to
analysis.Patients and methods
Between January 2007 and June 2013, 1494 cholecystec-
tomy cases due to acute calculous cholecystitis wered. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Pediatric or adolescent patients (age under 18), incom-
plete data, patients with GB cancer and patients without
laboratory results of bile or blood culture were all ex-
cluded from this study. The exact distribution of ex-
cluded cases are as follows: pediatric or adolescent
patients (2), incomplete data (10), GB cancer (6), cases
without laboratory results of bile culture (760), blood
culture (743), and both of cultures (166) (Figure 1).
A total of 139 eligible patients who had undergone
cholecystectomy for the treatment of acute calculous
cholecystitis were retrospectively investigated. The asso-
ciation between body mass index (BMI) with bactibilia
and bacteremia was assessed using univariate and multi-
variate analysis. Clinical findings and biliary infection re-
lated data were recorded for the following variables:
gender, age, alcohol and smoking history, the results of
blood and bile cultures, cholesterolosis, diabetes (DM),
hypertension (HTN), and duration of the hospital stay.
BMI (kg/m2) was calculated as the patient’s body weight
divided by the square of the height. The BMI was cate-
gorized and analyzed according to the recommendation
of World Health Organization Expert Consultation
(Asian population standard): stage 1 (<23), stage 2 (23 ≤
BMI < 25), and stage 3 (25 ≤ BMI) [8].
Blood culture was performed to identify the respon-
sible microorganism for the infection before initiating
antibiotics (BACTEC 9240 system). A minimum of
10 mL of blood was taken separately from more than
two different peripheral veins after cleansing the punc-
ture site and the top of the culture bottles with alcohol
or povidone-iodine sterilization. Bile culture was per-
formed using accessible specimen through percutaneous
transhepatic gallbladder drainage tube or endoscopic
nasobiliary drainage catheter after cleansing the tips of
the tube or catheter and the top of the culture bottles.
All the bacteriologic isolation and detection of theFigure 1 Study flow diagram.antimicrobial resistance procedure were performed by
the in-hospital laboratory medicine department. Micro-
bial culture rate from blood or bile and antimicrobial re-
sistance pattern was recorded and analyzed.
Statistical analysis
The continuous variables which showed normal distribu-
tion were expressed using the mean and standard devia-
tions (SD) and which did not show normal distribution
using the median and interquartile ranges. Student’s t test
and Mann–Whitney test were used to evaluate the con-
tinuous variables. Fisher’s exact test and linear-by-linear
association test were used to assess the categorical vari-
ables. A multivariate logistic regression test was used to
detect the independent risk factors related to bactibilia or
bacteremia. A p value < 0.05 was considered significant for
all tests. All the analysis were performed using the SPSS
software, version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristic of patients
Among the 139 eligible patients, 70 patients (50.4%)
showed bactibilia and 30 patients (21.6%) showed bacter-
emia. The median age was 68 (interquartile range: 58–75)
in the total enrolled population: 69.5 (58–75) in patients
with bactiblia, and 73 (61.75-81) in patients with bacter-
emia. Male predominance (59%) was observed in the total
number of the patients: patients with bactibilia (60%) and
with bacteremia (56.7%). The mean BMI (±SD) was 24 ±
3.4 in the total patients: 23.7 ± 3.8 in patients with bactibi-
lia, and 23.7 ± 4.2 with bacteremia. The distribution of
BMI stage in the total number of the patients is as follows:
stage 1 (41.7%), stage 2 (19.4%), and stage 3 (38.9%). The
clinical characteristics of the total enrolled patients are
summarized in Table 1. The clinical findings of the pa-
tients with bactibilia and bacteremia are shown in Tables 2
and 3, respectively.
Table 1 Clinical characteristics of total patients
Characteristics Total (n = 139)





Number of patients 20 (14.4%)
Alcohol (%)
Number of patients 36 (25.9%)
BMI, Mean ± SD 24 ± 3.4
BMI stage (%)
Stage 1 (<23) 58 (41.7%)
Stage 2 (23≤ BMI < 25) 27 (19.4%)
Stage 3 (25≤ BMI) 54 (38.9%)
Cholesterolosis (%) 12 (8.6%)
Duration of hospital stay 21.5 ± 15.8
Mean ± SD (days)
HTN (%) 60 (43.2%)
DM (%) 23 (16.5%)
BMI: Body mass index; SD: Standard deviation; HTN: Hypertension; DM: Diabetes
mellitus.




(n = 70, 50.4%) (n = 69, 49.6%)
Age (years), Median
(Interquartile range)
69.5 (58–75) 67 (57–76) 0.67
Sex, number (%) 0.86
Male 42 (60%) 40 (58%)
Female 28 (40%) 29 (42%)
Smoking (%) 0.23
Number of patients 13 (18.6%) 7 (10.1%)
Alcohol (%) 0.18
Number of patients 22 (31.4%) 14 (20.3%)
BMI, Mean ± SD 23.7 ± 3.8 24.2 ± 3.1 0.39
BMI stage (%) > 0.99
Stage 1 (<23) 29 (41.4%) 29 (42%)
Stage 2 (23≤ BMI < 25) 14 (20%) 13 (18.8%)
Stage 3 (25≤ BMI) 27 (38.6%) 27 (39.1%)
Cholesterolosis (%) 4 (5.7%) 8 (11.6%) 0.24
Duration of hospital stay
Mean ± SD (days)
22.4 ± 17 20.5 ± 14.4 0.49
HTN (%) 27 (38.6%) 33 (47.8%) 0.31
DM (%) 13 (18.6%) 10 (14.5%) 0.65
BMI: Body mass index; SD: Standard deviation; HTN: Hypertension; DM: Diabetes
mellitus.




(n = 30, 21.6%) (n = 109, 78.4%)
Age (years), Median
(Interquartile range)
73 (61.75–81) 67 (57.5–74) 0.02
Sex, number (%) 0.84
Male 17 (56.7%) 65 (59.6%)
Female 13 (43.3%) 44 (40.4%)
Smoking (%) 0.38
Number of patients 6 (20%) 14 (12.8%)
Alcohol (%) 0.64
Number of patients 9 (30%) 27 (24.8%)
BMI, Mean ± SD 23.7 ± 4.2 24 ± 3.2 0.70
BMI stage (%) 0.84
Stage 1 (<23) 14 (46.7%) 44 (40.4%)
Stage 2 (23≤ BMI < 25) 2 (6.7%) 25 (22.9%)
Stage 3 (25≤ BMI) 14 (46.7%) 40 (36.7%)
Cholesterolosis (%) 3 (10%) 9 (8.3%) 0.72
Duration of hospital stay
Mean ± SD (days)
20.8 ± 13.9 21.6 ± 16.3 0.80
HTN (%) 15 (50%) 45 (41.3%) 0.41
DM (%) 2 (6.7%) 21 (19.3%) 0.16
BMI: Body mass index; SD: Standard deviation; HTN: Hypertension; DM: Diabetes
mellitus.
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In the univariate analysis, bacteremia was associated with
bactibilia (OR: 4.33, p = 0.002). In patients with both of
bactibilia and bacteremia, 50% (11/22) showed concordant
cultured organism. However, BMI was not associated with
bacteremia or bactibilia, although there were inverse rela-
tion trends [(bactibilia vs. no bactibilia; 23.7 ± 3.8 vs. 24.2 ±
3.1, p = 0.39), (bacteremia vs. no bacteremia; 23.7 ± 4.2 vs.
24 ± 3.2, p = 0.70)]. BMI stage also showed associations
with neither the patients with bactibilia, nor the patients
with bacteremia (p > 0.99 and p = 0.84). Only the age was
different between the patients with bacteremia and the pa-
tients without bacteremia [median (interquartile ranges),
73 (61.75-81) vs. 67 (57.5-74), p = 0.02] (Tables 2 and 3).Multivariate analysis for bactibilia and bacteremia
In the multivariate analysis for the risk factors of bactibi-
lia, BMI and bacteremia were related with bactibilia
(OR: 0.59, 95% CI: 0.42-0.84, p = 0.003) (OR: 3.32, 95%
CI: 1.22-9, p = 0.02). In the multivariate analysis for the
risk factors of bacteremia, BMI, bactibilia and age were
related with bacteremia (OR: 0.76, 95% CI: 0.59-0.99,
p = 0.04) (OR: 3.46, 95% CI: 1.27-9.45, p = 0.02), (OR:
1.05, 95% CI: 1.01-1.09, p = 0.02) (Table 4).
Table 4 Multivariate logistic regression analysis for the risk factors of bactibilia and bacteremia
Variables for bactibilia OR (95% CI) p Variables for bactemia OR (95% CI) p
BMI 0.59 (0.42–0.84) 0.003 BMI 0.76 (0.59–0.99) 0.04
Bacteremia 3.32 (1.22–9) 0.02 Bactibilia 3.46 (1.27–9.45) 0.02
Age NS NS Age 1.05 (1.01–1.09) 0.02
BMI: Body mass index; NS: Statistically non-significant; OR: Odds ratio; CI: Confidence interval.
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The microbial culture rate of biliary bacteria and bac-
teremia were 50.4% and 21.6%, respectively. The most
common pathogen of bile and blood culture was com-
monly Escherichia coli (E. coli) [(n = 22, 31.4%), (n = 12,
40%)], followed by Klebsiella pneumonia (n = 19, 27.1%)
and Pseudomonas aeruginosa (n = 11, 15.7%) in the bile
samples, and Klebsiella pneumonia (n = 4, 13.3%), Pseudo-
monas aeruginosa (n = 4, 13.3%), and Staphylococcus spp.
(n = 6, 20%) in the blood samples (Table 5). Antimicrobial
resistance rate of E. coli was 59.1% of bile specimens and
16.7% of blood specimens. The proportion of extended-
spectrum beta-lactamase (ESBL) producing organism wasTable 5 Total isolated organisms in bile and blood culture
Organism
Bactibilia Bacteremia
(n = 70, 50.4%) (n = 30, 21.6%)
E. coli 22 (31.4%) 12 (40%)
Klebsiella spp. 19 (27.1%) 4 (13.3%)
Klebsiella pneumonia 17 (24.3%) 4 (13.3%)
Klebsiella ozaenae 1 (1.4%)
Klebsiella oxytoca 1 (1.4%)
Enterococcus spp. 14 (20%) 2 (6.7%)
Enterococcus faecium 6 (8.6%) 2 (6.7%)
Enterococcus casseliflavus 4 (5.7%)
Enterococcus faecalis 3 (4.3%)
Enterococcus durans 1 (1.4%)
Pseudomonas aeruginosa 11 (15.7%) 4 (13.3%)
Enterobacter cloacae 4 (5.7%)
Aeromonas spp. 2 (2.9%) 1 (3.3%)
Aeromonas hydrophilia 1 (1.4%)
Aeromonas veronii biovar sobria 1 (1.4%)
Stenotrophomonas maltophilia 2 (2.9%) ·
Raoultella planticola 1 (1.4%) ·
Acinetobacter baumannii 1 (1.4%) ·
Staphylococcus spp. 6 (20%)
Staphylococcus homonis 4 (13.3%)
Staphylococcus epidermidis 1 (3.3%)
Staphylococcus auricularis 1 (3.3%)
Streptococcus viridans · 1 (3.3%)
Morganella morganii · 1 (3.3%)
spp.: species.estimated as 27.3% of E. coli in bile specimens, but it was
not detected in the blood specimens (Table 6). Among the
Klebsiella pneumonia species (spp.), 52.9% showed ESBL
producing organism in bile specimens and 50% showed in
blood specimens. Vancomycin-resistant enterococci (VRE)
was detected only in Enterococcus casseliflavus spp. as
25%. One Acinetobacter baumannii was isolated from the
bile culture and was identified as imipenem-resistant
Acinetobacter baumannii (IRAB). One Staphylococcus
epidermidis was isolated from the blood culture and
was identified as Methicillin-resistant coagulase-negative
Staphylococci (MR-CNS) (Table 6).
Discussion
Bactibilia and bacteremia are serious manifestations of
acute cholecystitis and are known to be associated with
complications, mortality and prognosis [9,10]. The pre-
dictive factors for bactibilia have been proposed as
advanced age, high body temperature, and increased in-
flammatory markers such as high serum C-reactive pro-
tein [9,11]. However, the association between obesity
and bactibilia or bacteremia has not been established.
This study demonstrated that BMI is inversely corre-
lated with bactibilia and bacteremia in patients with
acute calculous cholecystitis. According to the study that
evaluated the association between BMI and the severity
of biliary infections in the United States (US), BMI was
not associated with bactibilia. However, BMI was in-
versely associated with the severity of biliary infections
and obesity was postulated as having protective effect on
severe infections [12]. From the findings of another
study of the Korean population, negative correlation was
observed between BMI and the severity of cholecystitis,
albeit this was proved only in men [13]. Despite the dif-
ferent study designs and study populations, these studies
all indicated that obesity is not associated with severe
form or complications of biliary infections. This finding
is contrary to the general belief that obese patients are
more susceptible to infections. Obesity is also known to
be a risk factor for increased morbidity and mortality
after infections [14].
Interesting data relevant to this finding is the in-
creased susceptibility or mortality following infection in
patients with lower BMI. According to a study of the US
population, underweight patients (BMI < 18.5) were as-
sociated with increased mortality from non-cancer and
Table 6 Antimicrobial resistance rate of isolated organisms
Organism Bactibilia (n = 70, 50.4%) Bacteremia (n = 30, 21.6%)
E. coli 13/22 (59.1%) ESBL: 6/22 (27.3%) 2/12 (16.7%) ESBL: 0
Klebsiella spp. 19/19 (100%) ESBL 17/19 (89.5%) 3/4 (75%) ESBL 2/4 (50%)
Klebsiella pneumonia 17/17 (100%) ESBL 9/17 (52.9%) 3/4 (75%) ESBL 2/4 (50%)
Klebsiella ozaenae 1/1 (100%)
Klebsiella oxytoca 1/1 (100%)
Enterococcus spp. 13/14 (92.9%) 2/2 (100%)
Enterococcus faecium 6/6 (100%) 2/2 (100%)
Enterococcus casseliflavus 4/4 (100%) VRE 1/4 (25%)
Enterococcus faecalis 3/3 (100%)
Enterococcus durans 0/1 (0%)
Pseudomonas aeruginosa 10/11 (90.9%) 4/4 (100%)
Enterobacter cloacae 4/4 (100%)
Aeromonas spp. 2/2 (100%) 1/1 (100%)
Aeromonas hydrophilia 1/1 (100%)
Aeromonas veronii biovar sobria 1/1 (100%)
Stenotrophomonas maltophilia 1/2 (50%) ·
Raoultella planticola 1/1 (100%) ·
Acinetobacter baumannii 1/1 (100%) IRAB 1/1 (100%) ·
Staphylococcus spp. · 6/6 (100%)
Staphylococcus homonis 4/4 (100%)
Staphylococcus epidermidis 1/1 (100%) MR-CNS 1/1 (100%)
Staphylococcus auricularis 1/1 (100%)
Streptococcus viridans · 1/1 (100%)
Morganella morganii · 1/1 (100%)
spp.: species, ESBL: extended-spectrum beta-lactamase, VRE: vancomycin-resistant enterococci, IRAB: imipenem-resistant Acinetobacter baumannii,
MR-CNS: Methicillin-resistant coagulase-negative Staphylococci.
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based study also demonstrated that lower BMI (<18)
was associated with mortality of pneumonia, however
high BMI (25 >) was postulated as a protective factor
[16]. In a study of large Korean cohort, BMI was in-
versely correlated with mortality from respiratory dis-
eases (tuberculosis, pneumonia, asthma, and chronic
obstructive pulmonary disease) [17]. Overall, many eco-
logic studies indicated that mortality from any cause and
BMI shows a J-shaped pattern [17,18]. However, the
exact reason or mechanism of increasing infection in pa-
tients with lower BMI is yet unclear and it needs to be
elucidated from further studies.
Another explanation is the protective effect of obesity
against bacterial infections. Obese patients are known to
have high plasma lipoprotein levels. Lipoprotein is
known to have capacity of binding and neutralizing lipo-
polysaccharide (LPS) and lipoteichoic acids which are
responsible for the activation of Toll-like receptor 4 me-
diated host-immune responses [19,20]. However, general
belief is still that patients with obesity are moresusceptible to infections [14]. Conflicting results that fit
the general belief like impaired lymphocyte proliferation
to polyclonal stimulation or pro-inflammatory state of
mononuclear cells in obese patients still exist [21,22].
The association between obesity and infection may not
be generalized. This might be site-specific. Biliary infec-
tions are characterized by ascending form from the duo-
denum or hematogenous spread from the portal vein,
which is called cholangiovenous reflux [12]. According
to the studies that evaluated the pathophysiology of bil-
iary bacterial infections, LPS induced inflammatory cyto-
kine activation was the important factor of illness
severity [23,24]. It is unclear whether obesity has a posi-
tive role in the prevention of biliary infections only. Site-
specific studies are needed to confirm this result.
In terms of the hormonal changes of obese patients,
adiponectin which is one of the important adipokines is
known to reduce proinflammatory cytokines and in-
crease anti-inflammatory cytokines [25]. However, an-
other important adipokine, leptin is known to have the
capacity to up-regulate vascular adhesion molecules, and
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combination of these adipokines is associated with meta-
bolic syndrome and the development of cancers, how-
ever the association between adipokines and infections
(bactibilia or bacteremia) is not well established. Consid-
ering the visceral fat that produces various adipokines,
studies on the role of visceral fat, including adipokines
will give clues about the inverse association between
obesity and biliary infections.
Another finding from this study was the bacteriologic
profiles of bactibilia and bacteremia. The microbial cul-
ture rates of biliary bacteria and bacteremia were not
different from those in previous studies (50.4%, 21.6%)
[11,12]. E. coli and Klebsiella spp. were the most preva-
lent biliary organisms in accordance with the Japanese
study [11]. However, the proportion of ESBL and VRE
was relatively high which means increased resistance
and unresponsiveness to previously used empirical anti-
biotics. Therefore, interpretation of these results de-
mands caution. Since, many cases were excluded from
this study due to the lack of laboratory results of bile
and blood cultures, only relatively serious cases could be
finally enrolled.
This study has several limitations. It was a retrospective
study from single teaching hospital and a small number of
patients was enrolled for the statistical analysis. Another
limitation is the lacking information about type and num-
ber of GB stone and Lipoprotein level was not measured
consistently from enrolled patients. However, contrary to
the previous studies that assessed the association between
obesity and the severity of biliary infections, this study
evaluated the direct association between obesity and bacti-
bilia and bacteremia in patients with cholecystitis.
Conclusions
In conclusion, BMI is inversely correlated with bacteremia
or bactibilia, which means obese or overweight patients
are less likely to be associated with bacteremia or bactibilia
in patients with acute calculous cholecystitis.
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